Seroprevalence of Zika Virus in Amphawa District, Thailand, after the 2016 Pandemic.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Dengue* ; Zika Virus* ; Zika Virus Infection*; Antibodies, Viral ; Enzyme-Linked Immunosorbent Assay/methods ; Humans ; Pandemics ; Seroepidemiologic Studies ; Serologic Tests ; Thailand/epidemiology

In 2016, Zika virus (ZIKV) infection was declared a public health emergency of international concern because of the neurological consequences in babies born to infected people. Because of the mild and nonspecific symptoms, serological tests are essential in epidemiological studies. However, cross-reactive antibodies between other Flaviviridae members may complicate the interpretation of results of these tests. This study investigated the seroprevalence of ZIKV infection in Samut Songkhram in central Thailand which was affected by the Zika outbreak of 2016. Three hundred and fifty volunteers aged 5-50 years in Amphawa District, Samut Songkhram, were enrolled between April 2017 and April 2018. ZIKV nonstructural protein 1 (NS1) immunoglobulin G enzyme-linked immunosorbent assay (ELISA) was used to screen serum samples collected on the first day of enrollment and after 6 and 12 months. The seroprevalence and seroconversion of ZIKV were assessed. Cases of ZIKV seroconversion were verified as evidence of ZIKV infection by NS1 blockade-of-binding ELISA and plaque reduction neutralization test (PRNT50). ZIKV seroprevalence in Amphawa was 15.1-17.8% with no significant change over the year. The total seroconversion rate throughout the year was 7/100 person-years. The ratio of asymptomatic to symptomatic infections was 4.5:1. The cases in our study confirmed the occurrence of occult ZIKV infections in the community. These undetected infections might promote the spread of ZIKV in vulnerable groups of the community.

N Engl J Med. 2009 Jun 11;360(24):2536-43. (PMID: 19516034)
Am J Trop Med Hyg. 1969 May;18(3):411-5. (PMID: 4976739)
Lancet. 2016 Aug 27;388(10047):891-7. (PMID: 27372398)
Clin Infect Dis. 2017 Nov 13;65(11):1829-1836. (PMID: 29020159)
Trans R Soc Trop Med Hyg. 1964 Jul;58:335-8. (PMID: 14175744)
Am J Trop Med Hyg. 2015 Aug;93(2):380-383. (PMID: 26101272)
Am J Trop Med Hyg. 2020 Nov 09;104(2):557-563. (PMID: 33241785)
J Clin Microbiol. 2019 Jan 30;57(2):. (PMID: 30429254)
Sci Rep. 2018 Nov 21;8(1):17193. (PMID: 30464242)
Trans R Soc Trop Med Hyg. 1963 Sep;57:364-71. (PMID: 14062273)
Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):9294-9299. (PMID: 30150394)
Trans R Soc Trop Med Hyg. 1952 Sep;46(5):509-20. (PMID: 12995440)
BMC Infect Dis. 2020 Dec 3;20(1):921. (PMID: 33272192)
Elife. 2020 Jan 28;9:. (PMID: 31987069)
Pathogens. 2019 Mar 06;8(1):. (PMID: 30845707)
PLoS One. 2021 Sep 13;16(9):e0257205. (PMID: 34516583)
Med Mal Infect. 2014 Jul;44(7):302-7. (PMID: 25001879)
Emerg Infect Dis. 2017 Apr;23(4):669-672. (PMID: 28084987)
N Engl J Med. 2019 Oct 10;381(15):1444-1457. (PMID: 31597021)
Viruses. 2021 Sep 10;13(9):. (PMID: 34578383)
Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8384-8389. (PMID: 28716913)
JAMA. 2017 Jan 3;317(1):59-68. (PMID: 27960197)
Science. 2016 Aug 12;353(6300):aaf8160. (PMID: 27417495)
MMWR Morb Mortal Wkly Rep. 2016 Jan 29;65(3):55-8. (PMID: 26820163)
Clin Microbiol Rev. 2016 Jul;29(3):487-524. (PMID: 27029595)
J Immunol. 1967 Aug;99(2):285-90. (PMID: 6031202)
Lancet Infect Dis. 2019 Apr;19(4):439-446. (PMID: 30826189)

Keywords: ELISA; PRNT; Thailand; Zika virus; epidemiology; flavivirus

0 (Antibodies, Viral)

Date Created: 20220326 Date Completed: 20220414 Latest Revision: 20220414

20221213

PMC8953292

10.3390/v14030476

35336883